84 related articles for article (PubMed ID: 26384804)
1. Multiple Hepatic Lesions in a Patient With a History of DCIS.
Jasem J; Altoos B; Fisher CM; Elias AD; Kounalakis N; Borges VF; Kabos P
Oncology (Williston Park); 2015 Sep; 29(9):669-70, 678-9. PubMed ID: 26384804
[No Abstract] [Full Text] [Related]
2. Can some DCIS patients avoid adjuvant therapy? Still unknown.
Schmidt C
J Natl Cancer Inst; 2011 Apr; 103(7):530-1. PubMed ID: 21436062
[No Abstract] [Full Text] [Related]
3. DCIS prognostic markers: a few new candidates emerge.
Nelson NJ
J Natl Cancer Inst; 2010 May; 102(9):588-90. PubMed ID: 20427428
[No Abstract] [Full Text] [Related]
4. Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ.
Aulmann S; Elsawaf Z; Penzel R; Schirmacher P; Sinn HP
Am J Surg Pathol; 2009 Nov; 33(11):1646-53. PubMed ID: 19675453
[TBL] [Abstract][Full Text] [Related]
5. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
6. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.
Moore KH; Sweeney KJ; Wilson ME; Goldberg JI; Buchanan CL; Tan LK; Liberman L; Turner RR; Lagios MD; Cody Iii HS; Giuliano AE; Silverstein MJ; Van Zee KJ
Ann Surg Oncol; 2007 Oct; 14(10):2911-7. PubMed ID: 17597346
[TBL] [Abstract][Full Text] [Related]
7. Ductal carcinoma in situ-like structures in metastatic breast carcinoma.
Kordek R
Pathol Res Pract; 2005; 200(11-12):831-4. PubMed ID: 15792128
[TBL] [Abstract][Full Text] [Related]
8. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
9. Luminal B breast tumors are not HER2 positive.
Bhargava R; Dabbs DJ
Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
[No Abstract] [Full Text] [Related]
10. [DCIS and HER2/neu].
Tulusan AH
Onkologie; 2002 Dec; 25 Suppl 5():11-2; discussion 13. PubMed ID: 23573612
[No Abstract] [Full Text] [Related]
11. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
[TBL] [Abstract][Full Text] [Related]
12. Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion.
Okumura Y; Yamamoto Y; Zhang Z; Toyama T; Kawasoe T; Ibusuki M; Honda Y; Iyama K; Yamashita H; Iwase H
BMC Cancer; 2008 Oct; 8():287. PubMed ID: 18837981
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
14. Microglandular adenosis with transition to breast carcinoma: a series of three cases.
Lin L; Pathmanathan N
Pathology; 2011 Aug; 43(5):498-503. PubMed ID: 21753716
[No Abstract] [Full Text] [Related]
15. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
16. Combined hepatocellular carcinoma - cholangiocarcinoma harboring a metastasis of colon adenocarcinoma.
Pintea B; Di Tommaso L; Destro A; Roncalli M
J Gastrointestin Liver Dis; 2013 Sep; 22(3):341-3. PubMed ID: 24078994
[TBL] [Abstract][Full Text] [Related]
17. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
18. Ductal carcinoma in situ: dilemma or denouement.
Lagios MD; Silverstein MJ
J Clin Oncol; 2010 May; 28(14):e218-9; author reply e220. PubMed ID: 20368539
[No Abstract] [Full Text] [Related]
19. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
20. Inclusion of tumor biology molecular markers to improve the ductal carcinoma in situ ipsilateral breast tumor recurrence nomogram predictability.
Ballehaninna UK; Chamberlain RS
J Clin Oncol; 2011 Feb; 29(4):e97-8; author reply e99. PubMed ID: 21172894
[No Abstract] [Full Text] [Related]
[Next] [New Search]
